HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
国際連携研究教育局 : GI-CoRE >
雑誌発表論文等  >

Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
s13014-016-0660-4.pdf573.41 kBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/68323

タイトル: Prognostic factors in clinical T1N0M0 thoracic esophageal squamous cell carcinoma invading the muscularis mucosa or submucosa
著者: Uchinami, Yusuke 著作を一覧する
Myojin, Miyako 著作を一覧する
Takahashi, Hiroaki 著作を一覧する
Harada, Keiichi 著作を一覧する
Shimizu, Shinichi 著作を一覧する
Hosokawa, Masao 著作を一覧する
キーワード: T1N0M0
Superficial esophageal cancer
Depth of tumor invasion
Chemoradiotherapy
Radiotherapy
Elective nodal irradiation
Endoscopic submucosal dissection
Endoscopic mucosal resection
発行日: 2016年 6月21日
出版者: BMC Urology
誌名: Radiation Oncology
巻: 11
開始ページ: 84
出版社 DOI: 10.1186/s13014-016-0660-4
抄録: Background: Multimodality treatment is widely performed for clinical T1N0M0 (UICC-TNM classification, 7th edition) thoracic esophageal squamous cell carcinoma (ESCC), but available articles regarding treatment results are limited. This study assessed the outcomes of clinical T1N0M0 thoracic ESCC invading the muscularis mucosa (MM) or submucosa (SM) treated with radiotherapy (RT) or chemoradiotherapy (CRT). Methods: We retrospectively reviewed the medical charts of 90 patients with clinical T1N0M0 thoracic ESCC treated with RT or CRT in our hospital in 2004?2011. Of these 90 patients, we analyzed the cases of 71 patients who met our inclusion criteria. All 71 patients had MM or SM cancer. In the 47 patients treated with CRT, the chemotherapy regimen of 5-fluorouracil (5-FU) plus cisplatin (CDDP) was used for 46 patients and 5-FU and nedaplatin was used for one patient. Forty-five patients underwent endoscopic resection (ER) followed by RT or CRT as an additional treatment. Elective nodal irradiation (ENI) was used in 39 patients. For all analyses, statistical significance was defined as 0.05, and the Bonferroni correction was used for the multivariate analysis. Results: The median age was 70 years (range 47?84). With a median follow-up of 43.6 months (range 1.5?124.2), the 5-year overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS) rates were 64.0, 72.8 and 50. 0 %, respectively. The multivariate analysis showed that performance status (PS) was an independent prognostic factors for DSS and DFS (DSS, p < 0.001; DFS, p < 0.001). Chemotherapy in addition to RT showed a trend for better DSS (p = 0.032) but was not significant following Bonferroni correction. ER and ENI were not significant predictive factors for DSS and DFS. Conclusions: PS was an independent prognostic factor for DSS and DFS. ER and ENI had no significant relationship with DSS or DFS. The present results may be helpful in treatment decisions for clinical T1N0M0 thoracic ESCC.
資料タイプ: article
URI: http://hdl.handle.net/2115/68323
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 清水 伸一

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学